drugset
drugset / Trial / NCT07123376

Pharmacokinetics, Pharmacodynamics Profile and Tolerance of HRS-9231 in Healthy Subjects

NCT07123376 ↗

Phase 1 Completed 40 enrolled Shanghai Shengdi Pharmaceutical Co., Ltd
RandomizedSequentialTriple-blindDiagnostic

Summary

To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of HRS-9231 injection in a single dose in healthy subjects

Timeline

Start
2024-06-05
Primary completion
2024-10-06
Completion
2024-10-06

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-9231 Diagnostic / imaging agent — Intravenous

Indications

No indication recorded.